Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 243

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier

Open access
Yonker, Lael M., Gilboa, Tal, Ogata, Alana F., Senussi, Yasmeen, Lazarovits, Roey, Boribong, Brittany P., Bartsch, Yannic C., Loiselle, Maggie, Rivas, Magali Noval, Porritt, Rebecca A., Lima, Rosiane, Davis, Jameson P., Farkas, Eva J., Burns, Madeleine D., Young, Nicola, Mahajan, Vinay S., Hajizadeh, Soroush, Lopez, Xcanda I. Herrera, Kreuzer, Johannes, Morris, Robert, Martinez, Enid E., Han, Isaac, Griswold, Kettner, Barry, Nicholas C., Thompson, David B., Church, George, Edlow, Andrea G., Haas, Wilhelm, Pillai, Shiv, Arditi, Moshe, Alter, Galit, Walt, David R., Fasano, Alessio · 2021 · Journal of Clinical Investigation

Abstract

BACKGROUNDWeeks after SARS-CoV-2 infection or exposure, some children develop a severe, life-threatening illness called multisystem inflammatory syndrome in children (MIS-C). Gastrointestinal (GI) symptoms are common in patients with MIS-C, and a severe hyperinflammatory response ensues with potential for cardiac complications. The cause of MIS-C has not been identified to date.METHODSHere, we analyzed biospecimens from 100 children: 19 with MIS-C, 26 with acute COVID-19, and 55 controls. Stools were assessed for SARS-CoV-2 by reverse transcription PCR (RT-PCR), and plasma was examined for markers of breakdown of mucosal barrier integrity, including zonulin. Ultrasensitive antigen detection was used to probe for SARS-CoV-2 antigenemia in plasma, and immune responses were characterized. As a proof of concept, we treated a patient with MIS-C with larazotide, a zonulin antagonist, and monitored the effect on antigenemia and the patient's clinical response.RESULTSWe showed that in children with MIS-C, a prolonged presence of SARS-CoV-2 in the GI tract led to the release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation. The patient with MIS-C treated with larazotide had a coinciding decrease in plasma SARS-CoV-2 spike antigen levels and inflammatory markers and a resultant clinical improvement above that achieved with currently available treatments.CONCLUSIONThese mechanistic data on MIS-C pathogenesis provide insight into targets for diagnosing, treating, and preventing MIS-C, which are urgently needed for this increasingly common severe COVID-19-related disease in children.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci149633

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 243

Metadata

Authors
Yonker, L. M., Gilboa, T., Ogata, A. F., Senussi, Y., Lazarovits, R., Boribong, B. P., Bartsch, Y. C., Loiselle, M., Rivas, M. N., Porritt, R. A., Lima, R., Davis, J. P., Farkas, E. J., Burns, M. D., Young, N., Mahajan, V. S., Hajizadeh, S., Lopez, X. I. H., Kreuzer, J., Morris, R., Martinez, E. E., Han, I., Griswold, K., Barry, N. C., Thompson, D. B., Church, G., Edlow, A. G., Haas, W., Pillai, S., Arditi, M., Alter, G., Walt, D. R., & Fasano, A.
Venue
Journal of Clinical Investigation
Published
2021-07-15
Volume
131
Issue
14
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3165602562
Cited by
243
References
13
FWCI
43.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.